PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS
← catalyst calendarSponsored by Precigen, Inc (industry) · PGEN — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
88estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-05-20 | actual | When the study began enrolling |
| Primary completion | 2024-08-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-01 | estimated | The whole study's end, after follow-up |
| First posted | 2019-04-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-11-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
Intervention
- Drug: PRGN-3006 T Cells
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants who Experience Dose Limiting Toxicities (DLTs)
measured Up to Day 42
Number of Participants who Experience Treatment Emergent Adverse Events (TEAEs)
measured Up to 12 months post treatment
Publications
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · PGEN's whole pipeline · Catalyst calendar · Every registered study · What changed